XDATA – September 22nd 2014
$21 million was raised by Eureka Therapeutics following the successful placement and issuance of its unregistered equity securities. A total of twenty-eight investors participated to the non-brokered placement which started one month ago. No offering was previously initiated by the company under a registration exemption with the SEC.
The company is engaged in the discovery of novel antibody immunotherapies. The company utilizes a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens.
The company, headquartered in Emeryville CA, is led by Cheng Liu (President). Eureka Therapeutics elected to keep its revenues undisclosed.
The board of directors includes Chih-kai Cheng, Hsing Kung, Qiushi Fu and Sandy Chau.
Company: Eureka Therapeutics
Amount offered: $21 million
Amount placed: $21 million
First sale: 08-20-2014
Data as of: 08-20-2014